Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2024

Janssen Pharmaceutica NV - Guiding clinical decision-making in advanced EGFR-mutant NSCLC

Advances in EGFR exon20ins mutations in NSCLC

Date

21 Mar 2024

Session

Janssen Pharmaceutica NV - Guiding clinical decision-making in advanced EGFR-mutant NSCLC

Presenters

Pascale Tomasini

Authors

P. Tomasini

Author affiliations

  • Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital La Timone, CEPCM, 21000 - Marseille/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introductions

Presenter: Martin Reck

Session: Janssen Pharmaceutica NV - Guiding clinical decision-making in advanced EGFR-mutant NSCLC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.